Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: Implications for AIDS vaccine development using Sendai virus vectors

• Published in: Human vaccines Vol. 7; no. 6; pp. 639 - 645
• Main Authors: Hara, Hiroto, Hironaka, Takashi, Inoue, Makoto, Iida, Akihiro, Shu, Tsugumine, Hasegawa, Mamoru, Nagai, Yoshiyuki, Falsey, Ann R., Kamali, Anatoli, Anzala, Omu, Sanders, Eduard J., Karita, Etienne, Mwananyanda, Lawrence, Vasan, Sandhya, Lombardo, Angela, Parks, Christopher L., Sayeed, Eddy, Krebs, Marietta, Cormier, Emmanuel, Ackland, James, Price, Matthew A., Excler, Jean-Louis
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 01.06.2011
• Subjects: Adolescent; Adult; Africa; AIDS Vaccines - immunology; Antibodies, Neutralizing - blood; Antibodies, Viral - blood; Binding; Biology; Bioscience; Calcium; Cancer; Cell; Cross Reactions; Cycle; Europe; Female; Genetic Vectors; Humans; Japan; Landes; Male; Middle Aged; Organogenesis; Parainfluenza Virus 1, Human - immunology; Proteins; Sendai virus - genetics; Sendai virus - immunology; United States; United States; Europe; Japan; Africa

A Sendai virus (SeV) vector is being developed for delivery of an HIV immunogen. SeV is not known to cause disease in humans. Because it is genetically and antigenically related to human parainfluenza virus type 1 (hPIV-1), it is important to determine whether pre-existing hPIV-1 antibodies will aff...